Degrading TBK1 to disarm VHL-deficient renal cancer.
Saved in:
| Title: | Degrading TBK1 to disarm VHL-deficient renal cancer. |
|---|---|
| Authors: | Kwon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Bers AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Parker Institute for Immunotherapy at the Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: david_barbie@dfci.harvard.edu. |
| Source: | Cell chemical biology [Cell Chem Biol] 2026 Apr 16; Vol. 33 (4), pp. 425-427. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101676030 Publication Model: Print Cited Medium: Internet ISSN: 2451-9448 (Electronic) Linking ISSN: 24519448 NLM ISO Abbreviation: Cell Chem Biol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
